Interbody Fusion Device MINNEAPOLIS, May 6 /PRNewswire-FirstCall/ -- Sulzer Spine-Tech, a subsidiary of Sulzer Medica Ltd. (NYSE: SM; Swiss Stock Market: SMEN), based in Minneapolis, Minnesota, has received U.S. Food and Drug Administration (FDA) approval to begin marketing the BP/Lordotic Interbody Fusion Device for use in anterior lumbar fusions. The BP/Lordotic device expands Spine-Tech's offering for the $180 million dollar anterior fusion market. "The BP/Lordotic cage is the only titanium threaded cage on the market today that offers surgeons a completely lordotic system. Each instrument in the BP/Lordotic system helps maintain lordosis from distraction to cage placement," said Mike McCormick, Executive Vice President and General Manager of Sulzer Spine-Tech. McCormick went on to say, "the spine is naturally curved or lordotic and it is important to maintain lordosis to ensure the best patient outcome. Spine-Tech has been known for its innovation with interbody devices, the BP/Lordotic System brings that innovation to the instruments as well." Lumbar fusions are a common treatment for disabling low back and leg pain stemming from degenerative disc diseases. The BP/Lordotic fusion system encompasses an 8 (lordotic angle in all instruments and implants to help restore lumbar lordosis. Since its inception in 1991, Sulzer Spine-Tech has focused on designing and manufacturing comprehensive spine care solutions to improve patients' quality of life. Sulzer Medica's subsidiary companies develop, produce, and distribute medical implants and biological materials for cardiovascular and orthopedic markets worldwide. The product array includes artificial joints, dental implants, spinal implants and instrumentation, trauma products, heart valves, synthetic blood vessels and stents for vascular and non-vascular obstructions. (Swiss Stock Market symbol: SMEN, New York Stock Exchange symbol: SM). THE SAFE HARBOR STATEMENTS UNDER THE U.S. PRIVATE SECURITIES LITIGATION REFORM ACT 1995 This report contains forward-looking statements including, but not limited to, projections of future performance of materials and products, financial conditions, results of operations and cash flows, containing risks and uncertainties. These statements are subject to change based on known risks detailed from time to time in the Company's Securities and Exchange Commission filings and other known and unknown risks and various other factors which could cause the actual results or performance to differ materially from the statements made herein. This news release is available on the Internet at: http://www.sulzermedica.com. The company's annual report 2001 is available on the Sulzer Medica corporate web site at http://www.sulzermedica.com "Investors" / "Financial reports". SOURCE Sulzer Medica Ltd. -0- 05/06/2002 /CONTACT: Media - Beatrice Tschanz, +41-1-306-96-46, fax - +41-1-306-98-37, mobile - +41-79-407-08-78, Andy Bantel, +41-1-306-96-53, fax - +41-1-306-96-51, mobile - +41-79-231-56-62, or email@example.com, or Investor Relations - Anja Stubenrauch, +41-1-306-98-25, fax - +41-1-306-98-31, or firstname.lastname@example.org, all of Sulzer Medica/ /Web site: http://www.sulzermedica.com/ (SM) CO: Sulzer Spine-Tech; Sulzer Medica Ltd. ST: Minnesota IN: HEA MTC SU: EXE -0- May/06/2002 6:48 GMT
Sulzer Spine-Tech Receives FDA-approval for the BP/Lordotic
Press spacebar to pause and continue. Press esc to stop.